PBH:NYE-Prestige Brand Holdings Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 78.75

Change

+0.19 (+0.24)%

Market Cap

N/A

Volume

0.09M

Analyst Target

USD 45.75
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+0.42 (+0.26%)

USD 74.37B
HLN Haleon plc

+0.02 (+0.21%)

USD 44.13B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 42.24B
RDY Dr. Reddy’s Laboratories Ltd..

+0.18 (+1.16%)

USD 13.11B
CTLT Catalent Inc

N/A

USD 11.52B
ELAN Elanco Animal Health

+0.02 (+0.17%)

USD 5.75B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.06 (+0.77%)

USD 3.59B
BHC Bausch Health Companies Inc

+0.05 (+0.67%)

USD 2.75B
CPHI China Pharma Holdings Inc

+0.01 (+5.00%)

USD 3.69M
YCBD cbdMD Inc

+0.01 (+2.28%)

USD 1.96M

ETFs Containing PBH

NDIA Global X Funds 3.44 % 0.00 %

+0.05 (+0.11%)

USD 0.03B
XST:CA iShares S&P/TSX Capped Co.. 2.67 % 0.61 %

-0.07 (0.11%)

CAD 0.27B
EMC Global X Funds 2.40 % 0.00 %

+0.03 (+0.11%)

USD 0.11B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 28.63% 73% C 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.63% 73% C 83% B
Trailing 12 Months  
Capital Gain 27.57% 73% C 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.57% 73% C 83% B
Trailing 5 Years  
Capital Gain 94.59% 93% A 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 94.59% 86% B+ 84% B
Average Annual (5 Year Horizon)  
Capital Gain 18.15% 80% B- 79% B-
Dividend Return 18.15% 80% B- 77% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.04% 73% C 52% F
Risk Adjusted Return 86.24% 100% F 91% A-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:

There is nothing we particularly dislike